Hilltop BioSciences Introduces New Regenerative Therapy Formulations for Companion Animals at VMX (Booth s5027)
10 Jan 2023
MANSFIELD, MA, January 10, 2023 -- Hilltop BioSciences, a veterinary biotech company pioneering the development of innovative regenerative therapies, will be introducing several new formulations at VMX in Orlando where they will be showcased in the Startup Circle (Booth s5027).
Already established in the equine arena, Regenaflex stimulates cell-to-cell communication that is essential for healing soft tissue by delivering an intracellular, cell-signaling cascade of cytokines, microRNA, growth factors and exosomes to the affected area. (Read more about the active components in Hilltop Bio’s products).
"Regenaflex has significant potential in the companion animal marketplace," says Hilltop Bio Chief Executive Officer Amanda Drobnis. "We look forward to introducing our innovative regenerative products at VMX."
Regenaflex can be reconstituted and ready to use in under a minute. Unlike other biologics, such as platelet-rich plasma (PRP), stem cell, and conditioned serum products, Hilltop Bio’s products offer long-term room-temperature storage, have consistent composition in every dose, require no special equipment or time-consuming processing, and are formulated to target specific indications.
The three new formulations include:
Regenaflex-K9 - An advanced regenerative soft tissue therapy tailored for practical application in veterinary practices. It establishes normal tissue functionality in treating acute trauma, chronic infections, and inflammation, nonhealing wounds, anal gland abscesses and fistulae.
Regenaflex-M Biofilm - A clinically proven anti-inflammatory, antimicrobial, and anti-adhesion scaffold formulation that accelerates tissue healing. Literature has shown, the Biofilm minimizes scar tissue formation without development of postoperative adhesions following abdominal or orthopedic surgery. It has also been shown to prevent postoperative suture leakage following intestinal anastomosis or cystotomy.
PureOptic - Easy-to-use eye drops that include the same power-packed regenerative cargo as Hilltop’s other products and literature has shown can be used to normalize damaged tissue resulting from eye injuries or disease.
According to Heather Sherman, DVM, "This was kind of a slam dunk case. There was no negative reaction to [Regenaflex] and the leg responded better than I would’ve expected given the animal’s age and the absence of any adjunctive therapies."
Veterinarians interested in participating in Hilltop Bio’s planned clinical trials should inquire about enrolling their patients.
About Hilltop Biosciences
Located at the Mansfield BioIncubator in Massachusetts, Hilltop Bio is an innovative veterinary biotech company that develops targeted regenerative therapies to help reduce inflammation, accelerate healing, and normalize damaged tissue function in horses and companion animals. The company is leveraging its intellectual property portfolio into a strong pipeline of off-the-shelf, room temperature biologic products. The company's recent round of funding was led by Launchpad Venture Group and several other Boston-based funding groups.
To learn more about Hilltop Bio, visit HilltopBio.com or find them on Facebook, Instagram, and LinkedIn.
Contact:
Andrew Lavin
A. Lavin Communications
516-944-4486
andrewlavin@alavin.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.